ES2639121T3 - Péptidos señuelo que inhiben la desfosforilación de fosfolambano mediada por la proteína fosfatasa 1 - Google Patents

Péptidos señuelo que inhiben la desfosforilación de fosfolambano mediada por la proteína fosfatasa 1 Download PDF

Info

Publication number
ES2639121T3
ES2639121T3 ES13812631.3T ES13812631T ES2639121T3 ES 2639121 T3 ES2639121 T3 ES 2639121T3 ES 13812631 T ES13812631 T ES 13812631T ES 2639121 T3 ES2639121 T3 ES 2639121T3
Authority
ES
Spain
Prior art keywords
amino acid
plb
ψplb
glu
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13812631.3T
Other languages
English (en)
Spanish (es)
Inventor
Woo Jin Park
Roger J. Hajjar
Jae Gyun Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gwangju Institute of Science and Technology
Original Assignee
Gwangju Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwangju Institute of Science and Technology filed Critical Gwangju Institute of Science and Technology
Application granted granted Critical
Publication of ES2639121T3 publication Critical patent/ES2639121T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES13812631.3T 2012-07-05 2013-07-05 Péptidos señuelo que inhiben la desfosforilación de fosfolambano mediada por la proteína fosfatasa 1 Active ES2639121T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668034P 2012-07-05 2012-07-05
US201261668034P 2012-07-05
PCT/KR2013/006009 WO2014007584A1 (en) 2012-07-05 2013-07-05 Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban

Publications (1)

Publication Number Publication Date
ES2639121T3 true ES2639121T3 (es) 2017-10-25

Family

ID=49882272

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13812631.3T Active ES2639121T3 (es) 2012-07-05 2013-07-05 Péptidos señuelo que inhiben la desfosforilación de fosfolambano mediada por la proteína fosfatasa 1

Country Status (6)

Country Link
US (3) US10208085B2 (enExample)
EP (1) EP2870171B1 (enExample)
JP (1) JP6404213B2 (enExample)
KR (1) KR101516791B1 (enExample)
ES (1) ES2639121T3 (enExample)
WO (1) WO2014007584A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530278A4 (en) * 2016-10-24 2019-10-30 Gwangju Institute of Science and Technology COMPOSITION WITH PROTEIN-PHOSPHATASE-1-INHIBITING PEPTIDE FOR THE TREATMENT OF VASCULAR DISEASES
EP4722234A1 (en) * 2023-06-05 2026-04-08 BethphaGen Inc. Gene construct comprising nucleotides encoding decoy peptides for inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban and nucleotides encoding ccn5 protein or fragments thereof, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711100A (en) * 1998-11-02 2000-05-22 Regents Of The University Of California, The A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
US20040121942A1 (en) 1999-11-02 2004-06-24 Kenneth Chien Method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040214760A1 (en) * 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１
US8455628B2 (en) 2007-05-02 2013-06-04 Intrexon Corporation PP1 ligands
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection

Also Published As

Publication number Publication date
EP2870171A1 (en) 2015-05-13
KR20140010889A (ko) 2014-01-27
US10208085B2 (en) 2019-02-19
KR101516791B1 (ko) 2015-05-04
EP2870171B1 (en) 2017-06-28
WO2014007584A1 (en) 2014-01-09
US10479816B2 (en) 2019-11-19
US20190112338A1 (en) 2019-04-18
USRE48636E1 (en) 2021-07-13
US20150166603A1 (en) 2015-06-18
JP2016500647A (ja) 2016-01-14
JP6404213B2 (ja) 2018-10-10
EP2870171A4 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
JP7537678B2 (ja) 自己組織化ペプチドを含む組成物
DK2707014T3 (en) Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain
JP6941605B2 (ja) 望まれない細胞増殖の除去又は破壊を必要とする疾患を治療するための組み合わせ組成物
US12351609B2 (en) Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
EA006603B1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
BRPI0708737A2 (pt) mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
JP6883048B2 (ja) 前立腺癌の進行を予防または緩和する小型神経糸ペプチド
ES2295347T3 (es) Uso de proteinas de la cadena neural para tratar tumores.
ES2319454T9 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
JP2018505188A (ja) 細胞の破壊又は除去を必要とする疾患を治療する方法
BRPI0208870B1 (pt) método de produção de polipeptídeos, vetor, composição farmacêutica, bem como método para diagnóstico de distrofia retinal
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
Marsh et al. Orally Delivered Milk-Derived Nanovesicles Loaded with Connexin 43 Peptides for Targeted Cardiac Ischemia-Reperfusion Therapy
US10479816B2 (en) Decoy peptides inhibiting protein phosphatase 1-medicated dephosphorylation of phospholamban
JP7805589B2 (ja) 自己組織化ペプチド
WO2021003800A1 (zh) 骨重建调节多肽及应用
ES3006614T3 (en) Relaxin receptor 1 for use in treatment and prevention of heart failure
WO2006041205A1 (ja) 血管形成促進剤
EP2419119B1 (en) Muscle function enhancing peptide
JP6068347B2 (ja) 筋機能を増強させる短ペプチド
WO2015169225A1 (zh) 四分支多肽化合物及其制备方法与应用
WO2025033256A1 (ja) ペプチドフラグメント及びその利用
WO2025033255A1 (ja) ペプチドフラグメント及びその利用
Rasmussen Mitochondrial calcium uniporter is a nodal regulator of physiological and pathological stress responses in myocardium